PRRT2 and melanoma: We next examined ZEB1 and PKC-θ expression in CD8+ T cells isolated from liquid biopsies of metastatic stage IV melanoma patients stratified based on RECIST v1.1 into responder, primary resistance, or secondary resistance (resistant after an initial positive response to immunotherapy).